Scalper1 News
Big biotech Celgene (CELG) rolled out more data on its new drug for Crohn’s disease Tuesday, sending Celgene shares up 3% in the stock market today. On Monday, Celgene released the abstract on the phase two trial of GED-0301, also called Mongersen, which showed good results for patients after two weeks of taking the drug. On Tuesday, it presented the full data at the United European Gastroenterology Week in Vienna, revealing that four-week and Scalper1 News
Scalper1 News